Antares Pharma, Inc.(ATRS): For the most recent quarter end, Antares Pharma, Inc. reported Annual Earnings of $-0.04. Based on the filings, last years Annual Earnings was, $-0.14. For the most recent quarter end, ATRS reported a surprise Earnings per Share of 0% . The consensus estimate for current quarter is $-0.04 and for the current fiscal year, the estimate is $-0.17. For the Next fiscal year, the estimate is $-0.1 based on the consensus. Ewing based Antares Pharma, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 14, 2017.
Antares Pharma, Inc. has received $-0.04 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.04 while the top line estimate is $-0.04 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 0%. According to the corporate earnings calendar, Antares Pharma, Inc. will release next earnings on Mar 14, 2017 with an estimated EPS consensus of $-0.04. Based on the consensus of stock financial advisors the stock has a price target of $2.83. Current year estimate on EPS consensus is $-0.17.
For Dividend Investing Stock Market Traders Antares Pharma, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0.
Company has reported several Insider transactions to the SEC, on Dec 12, 2016, Fred M Powell (CFO) purchased 100,000 shares at 2.03 per share price.On Dec 5, 2016, Leonard S Jacob (director) sold 20,000 shares at 1.97 per share price.On Mar 23, 2016, Peter J Graham (SVP General Counsel, Secretary) purchased 20,000 shares at 0.77 per share price.
Antares Pharma, Inc. (NASDAQ:ATRS) witnessed a decline in the market cap on Wednesday as its shares dropped 4.05% or 0.1 points. After the session commenced at $2.45, the stock reached the higher end at $2.5 while it hit a low of $2.35. With the volume soaring to 867,396 shares, the last trade was called at $2.37. The company has a 52-week high of $2.67. The company has a market cap of $368 million and there are 155,086,730 shares in outstanding. The 52-week low of the share price is $0.67.
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.